US 12,082,575 B2
Perfusion solution
Franklin Rosenfeldt, North Balwyn (AU); Marlin Alford, Kaufman, TX (US); and Robert Dowben, Providence, RI (US)
Assigned to Organ Transport Pty Ltd, North Adelaide (AU)
Filed by Organ Transport Pty Ltd, North Adelaide (AU)
Filed on May 8, 2015, as Appl. No. 14/708,159.
Application 14/708,159 is a division of application No. 13/818,670, granted, now 9,060,507, issued on Jun. 23, 2015, previously published as PCT/AU2011/001121, filed on Sep. 11, 2011.
Claims priority of provisional application 61/379,207, filed on Sep. 1, 2010.
Claims priority of provisional application 61/474,722, filed on Apr. 12, 2011.
Prior Publication US 2021/0307316 A1, Oct. 7, 2021
Int. Cl. A01N 1/02 (2006.01)
CPC A01N 1/0226 (2013.01) 6 Claims
 
1. A method of preserving a donor heart for transplantation after cardiac death by microperfusion of organ vasculature at 2 to 6 degrees C. comprising:
arresting the donor heart using a first cardioplegic aqueous solution comprising St. Thomas's Hospital No. 2 solution containing:
(a) 14 mM sodium-L-aspartate;
(b) 5 mg/L adenosine;
(c) 100 units/L regular insulin; and
(d) 5 mg/L cyclosporine;
harvesting the donor heart;
flushing the harvested donor heart with a second cardioplegic aqueous solution comprising St. Thomas's Hospital No. 2 solution containing:
(a) 14 mM sodium-L-aspartate;
(b) 10 mM sodium bicarbonate; and
(c) 7.6 mg/L-cariporide or equivalent sodium-hydrogen ion exchange inhibitor;
preparing a sterile aqueous solution for microperfusion containing:
(a) between 10 and 20 mM potassium chloride;
(b) between 5 and 10 mM magnesium;
(c) between 0.2 and 1.0 mM calcium;
(d) between 10 and 40 mM Tris(hydroxymethyl)aminomethane hydrochloride (Tris or THAM), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HE PES), 3-(N-morpholino)propanesulfonic acid (MOPS), 2-(N-morpholino)ethanesulfonic acid (MES), N,N-bis-(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), or Ntris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES);
(e) between 10 and 30 mM sodium bicarbonate, for enhancing out-flow of CO2 from cells;
(f) between 1 and 40 mM aspartate;
(g) between 1 and 30 mM glucose;
(h) between 1 and 20 mM adenosine, cAMP or cGMP;
(i) between 30 and 100 mM lactobionate; and
(k) a diluent;
injecting into the sterile aqueous solution, a mixture containing:
(a) between 1 and 20 units/L insulin;
(b) between 1 and 10 mM fructose diphosphate or a salt thereof; and
(c) between 1 and 10 mM reduced glutathione;
and
microperfusing the donor heart with the injected sterile aqueous solution while maintaining the donor heart and the injected sterile aqueous solution at a temperature between 2 and 6 degrees C., the microperfusing using only gravity to draw the injected sterile aqueous solution through the donor heart in a single microperfusion pass, wherein ionic strength of sodium in the sterile aqueous solution is maintained between 110 and 120 mM.